Aventis (Bridgewater, NJ) has received approval for the OptiClik reusable pen. This 24-hour insulin glargine [rDNA origin] injection (Lantus) is indicated for the control of hyperglycemia in type 1 and type 2 diabetics.

Lantus is indicated for once-daily subcutaneous administration in the treatment of adult patients with type 2 diabetes who require basal insulin, as well as for adult and pediatric patients 6 years of age and older with type 1 diabetes. Insulin glargine rDNA cannot be diluted or mixed with any other insulin.

According to Aventis, the OptiClik pen provides patients with a new, more precise, and easy-to-use delivery option that complements insulin glargine rDNA.

For more information, visit http://www.aventis-us.com.